Andrew Fein
Stock Analyst at HC Wainwright & Co.
(3.83)
# 766
Out of 4,412 analysts
349
Total ratings
43.23%
Success rate
10.28%
Average return
Main Sectors:
53 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BPMC Blueprint Medicines | Reiterates: Buy | $125 | $93.00 | +34.41% | 11 | Apr 26, 2024 | |
| BIIB Biogen | Maintains: Buy | $325 → $300 | $208.90 | +43.61% | 13 | Apr 25, 2024 | |
| NBIX Neurocrine Biosciences | Reiterates: Buy | $150 | $135.99 | +10.30% | 7 | Apr 24, 2024 | |
| UBX Unity Biotechnology | Maintains: Buy | $10 → $8 | $1.50 | +433.33% | 5 | Apr 16, 2024 | |
| ARVN Arvinas | Maintains: Buy | $90 → $87 | $32.37 | +168.77% | 9 | Apr 15, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $457 → $462 | $397.48 | +16.23% | 15 | Apr 11, 2024 | |
| AMLX Amylyx Pharmaceuticals | Reiterates: Buy | $8 | $1.76 | +354.55% | 12 | Apr 11, 2024 | |
| FHTX Foghorn Therapeutics | Reiterates: Buy | $20 | $5.49 | +264.30% | 9 | Apr 10, 2024 | |
| TARA Protara Therapeutics | Maintains: Buy | $23 | $2.93 | +686.32% | 9 | Apr 8, 2024 | |
| SYRS Syros Pharmaceuticals | Reiterates: Buy | $15 | $5.04 | +197.62% | 9 | Apr 1, 2024 | |
| VIGL Vigil Neuroscience | Maintains: Buy | $24 | $2.71 | +785.61% | 5 | Mar 27, 2024 | |
| ABOS Acumen Pharmaceuticals | Maintains: Buy | $15 | $3.17 | +373.19% | 6 | Mar 27, 2024 | |
| ANNX Annexon | Maintains: Buy | $30 | $4.70 | +538.30% | 9 | Mar 27, 2024 | |
| STOK Stoke Therapeutics | Reiterates: Buy | $35 | $12.41 | +182.03% | 7 | Mar 26, 2024 | |
| STRO Sutro Biopharma | Maintains: Buy | $16 | $3.42 | +367.84% | 8 | Mar 26, 2024 | |
| IMAB I-Mab | Reiterates: Buy | $18 → $8 | $1.80 | +344.44% | 8 | Mar 18, 2024 | |
| ACIU AC Immune | Reiterates: Buy | $16 | $2.35 | +580.85% | 9 | Mar 15, 2024 | |
| LQDA Liquidia | Maintains: Buy | $16 → $32 | $12.53 | +155.39% | 5 | Mar 14, 2024 | |
| PRQR ProQR Therapeutics | Reiterates: Buy | $5 | $1.94 | +157.73% | 7 | Mar 14, 2024 | |
| PRTA Prothena Corporation | Maintains: Buy | $90 | $20.87 | +331.24% | 9 | Mar 13, 2024 | |
| KALV KalVista Pharmaceuticals | Reiterates: Buy | $24 | $10.78 | +122.63% | 8 | Mar 12, 2024 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Buy | $33 | $16.71 | +97.49% | 13 | Mar 12, 2024 | |
| SVRA Savara | Reiterates: Buy | $6 | $4.41 | +36.05% | 5 | Mar 11, 2024 | |
| TCRX TScan Therapeutics | Reiterates: Buy | $15 | $7.32 | +104.92% | 7 | Mar 7, 2024 | |
| KMDA Kamada | Reiterates: Buy | $11 | $5.15 | +113.59% | 5 | Mar 7, 2024 | |
| WVE Wave Life Sciences | Maintains: Buy | $8 → $15 | $4.66 | +221.89% | 5 | Mar 7, 2024 | |
| DYN Dyne Therapeutics | Reiterates: Buy | $36 | $24.73 | +45.57% | 2 | Mar 6, 2024 | |
| KROS Keros Therapeutics | Reiterates: Buy | $100 | $57.86 | +72.83% | 7 | Mar 1, 2024 | |
| CPRX Catalyst Pharmaceuticals | Reiterates: Buy | $24 | $14.89 | +61.18% | 8 | Mar 1, 2024 | |
| MRUS Merus | Maintains: Buy | $48 → $65 | $45.04 | +44.32% | 9 | Feb 29, 2024 | |
| FULC Fulcrum Therapeutics | Maintains: Buy | $14 → $17 | $7.14 | +138.10% | 10 | Feb 28, 2024 | |
| ZNTL Zentalis Pharmaceuticals | Reiterates: Buy | $46 | $11.06 | +315.91% | 11 | Feb 28, 2024 | |
| DNLI Denali Therapeutics | Maintains: Buy | $105 → $95 | $15.43 | +515.68% | 10 | Feb 28, 2024 | |
| ALEC Alector | Reiterates: Buy | $41 | $5.25 | +680.95% | 5 | Feb 28, 2024 | |
| UTHR United Therapeutics | Reiterates: Buy | $300 | $233.85 | +28.29% | 7 | Feb 22, 2024 | |
| DBVT DBV Technologies | Reiterates: Buy | $10 | $0.68 | +1,366.28% | 6 | Feb 21, 2024 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $85 → $30 | $33.37 | -10.10% | 3 | Nov 3, 2023 | |
| CCCC C4 Therapeutics | Maintains: Buy | $17 → $7 | $6.17 | +13.45% | 6 | Nov 2, 2023 | |
| DCPH Deciphera Pharmaceuticals | Maintains: Buy | $25 → $30 | $14.65 | +104.78% | 10 | Oct 31, 2023 | |
| PEPG PepGen | Reiterates: Buy | $26 | $11.93 | +117.94% | 6 | Sep 7, 2023 | |
| INSM Insmed | Reiterates: Buy | $52 | $24.80 | +109.68% | 4 | Sep 6, 2023 | |
| PULM Pulmatrix | Reiterates: Buy | $10 | $2.04 | +390.20% | 5 | Aug 15, 2023 | |
| BCRX BioCryst Pharmaceuticals | Reiterates: Buy | $30 | $4.16 | +621.15% | 4 | Aug 4, 2023 | |
| BLPH Bellerophon Therapeutics | Maintains: Buy | $30 → $2 | $0.06 | +3,529.76% | 4 | Jun 6, 2023 | |
| CRBP Corbus Pharmaceuticals Holdings | Reiterates: Buy | $3 | $34.25 | -91.24% | 2 | Mar 8, 2023 | |
| MEIP MEI Pharma | Maintains: Buy | $100 → $40 | $3.05 | +1,211.48% | 2 | Feb 13, 2023 | |
| MTNB Matinas BioPharma Holdings | Reiterates: Buy | $3 | $0.18 | +1,576.91% | 1 | Jan 31, 2023 | |
| ELOX Eloxx Pharmaceuticals | Maintains: Neutral | $40 → $20 | $0.81 | +2,382.04% | 4 | May 9, 2022 | |
| AMRN Amarin Corporation | Downgrades: Neutral | $10 → $3 | $0.87 | +242.90% | 1 | May 5, 2022 | |
| ALDX Aldeyra Therapeutics | Assumes: Buy | $15 | $3.93 | +281.68% | 1 | Apr 27, 2022 | |
| APRE Aprea Therapeutics | Maintains: Neutral | $80 → $40 | $5.20 | +669.23% | 3 | Mar 16, 2022 | |
| OCUP Ocuphire Pharma | Initiates: Buy | n/a | $1.61 | - | 1 | Nov 24, 2021 | |
| TBIO Telesis Bio | Maintains: Buy | n/a | $0.32 | - | 2 | Mar 18, 2021 |
Blueprint Medicines
Apr 26, 2024
Reiterates: Buy
Price Target: $125
Current: $93.00
Upside: +34.41%
Biogen
Apr 25, 2024
Maintains: Buy
Price Target: $325 → $300
Current: $208.90
Upside: +43.61%
Neurocrine Biosciences
Apr 24, 2024
Reiterates: Buy
Price Target: $150
Current: $135.99
Upside: +10.30%
Unity Biotechnology
Apr 16, 2024
Maintains: Buy
Price Target: $10 → $8
Current: $1.50
Upside: +433.33%
Arvinas
Apr 15, 2024
Maintains: Buy
Price Target: $90 → $87
Current: $32.37
Upside: +168.77%
Vertex Pharmaceuticals
Apr 11, 2024
Maintains: Buy
Price Target: $457 → $462
Current: $397.48
Upside: +16.23%
Amylyx Pharmaceuticals
Apr 11, 2024
Reiterates: Buy
Price Target: $8
Current: $1.76
Upside: +354.55%
Foghorn Therapeutics
Apr 10, 2024
Reiterates: Buy
Price Target: $20
Current: $5.49
Upside: +264.30%
Protara Therapeutics
Apr 8, 2024
Maintains: Buy
Price Target: $23
Current: $2.93
Upside: +686.32%
Syros Pharmaceuticals
Apr 1, 2024
Reiterates: Buy
Price Target: $15
Current: $5.04
Upside: +197.62%
Vigil Neuroscience
Mar 27, 2024
Maintains: Buy
Price Target: $24
Current: $2.71
Upside: +785.61%
Acumen Pharmaceuticals
Mar 27, 2024
Maintains: Buy
Price Target: $15
Current: $3.17
Upside: +373.19%
Annexon
Mar 27, 2024
Maintains: Buy
Price Target: $30
Current: $4.70
Upside: +538.30%
Stoke Therapeutics
Mar 26, 2024
Reiterates: Buy
Price Target: $35
Current: $12.41
Upside: +182.03%
Sutro Biopharma
Mar 26, 2024
Maintains: Buy
Price Target: $16
Current: $3.42
Upside: +367.84%
I-Mab
Mar 18, 2024
Reiterates: Buy
Price Target: $18 → $8
Current: $1.80
Upside: +344.44%
AC Immune
Mar 15, 2024
Reiterates: Buy
Price Target: $16
Current: $2.35
Upside: +580.85%
Liquidia
Mar 14, 2024
Maintains: Buy
Price Target: $16 → $32
Current: $12.53
Upside: +155.39%
ProQR Therapeutics
Mar 14, 2024
Reiterates: Buy
Price Target: $5
Current: $1.94
Upside: +157.73%
Prothena Corporation
Mar 13, 2024
Maintains: Buy
Price Target: $90
Current: $20.87
Upside: +331.24%
KalVista Pharmaceuticals
Mar 12, 2024
Reiterates: Buy
Price Target: $24
Current: $10.78
Upside: +122.63%
ACADIA Pharmaceuticals
Mar 12, 2024
Reiterates: Buy
Price Target: $33
Current: $16.71
Upside: +97.49%
Savara
Mar 11, 2024
Reiterates: Buy
Price Target: $6
Current: $4.41
Upside: +36.05%
TScan Therapeutics
Mar 7, 2024
Reiterates: Buy
Price Target: $15
Current: $7.32
Upside: +104.92%
Kamada
Mar 7, 2024
Reiterates: Buy
Price Target: $11
Current: $5.15
Upside: +113.59%
Wave Life Sciences
Mar 7, 2024
Maintains: Buy
Price Target: $8 → $15
Current: $4.66
Upside: +221.89%
Dyne Therapeutics
Mar 6, 2024
Reiterates: Buy
Price Target: $36
Current: $24.73
Upside: +45.57%
Keros Therapeutics
Mar 1, 2024
Reiterates: Buy
Price Target: $100
Current: $57.86
Upside: +72.83%
Catalyst Pharmaceuticals
Mar 1, 2024
Reiterates: Buy
Price Target: $24
Current: $14.89
Upside: +61.18%
Merus
Feb 29, 2024
Maintains: Buy
Price Target: $48 → $65
Current: $45.04
Upside: +44.32%
Fulcrum Therapeutics
Feb 28, 2024
Maintains: Buy
Price Target: $14 → $17
Current: $7.14
Upside: +138.10%
Zentalis Pharmaceuticals
Feb 28, 2024
Reiterates: Buy
Price Target: $46
Current: $11.06
Upside: +315.91%
Denali Therapeutics
Feb 28, 2024
Maintains: Buy
Price Target: $105 → $95
Current: $15.43
Upside: +515.68%
Alector
Feb 28, 2024
Reiterates: Buy
Price Target: $41
Current: $5.25
Upside: +680.95%
United Therapeutics
Feb 22, 2024
Reiterates: Buy
Price Target: $300
Current: $233.85
Upside: +28.29%
DBV Technologies
Feb 21, 2024
Reiterates: Buy
Price Target: $10
Current: $0.68
Upside: +1,366.28%
Kymera Therapeutics
Nov 3, 2023
Maintains: Buy
Price Target: $85 → $30
Current: $33.37
Upside: -10.10%
C4 Therapeutics
Nov 2, 2023
Maintains: Buy
Price Target: $17 → $7
Current: $6.17
Upside: +13.45%
Deciphera Pharmaceuticals
Oct 31, 2023
Maintains: Buy
Price Target: $25 → $30
Current: $14.65
Upside: +104.78%
PepGen
Sep 7, 2023
Reiterates: Buy
Price Target: $26
Current: $11.93
Upside: +117.94%
Insmed
Sep 6, 2023
Reiterates: Buy
Price Target: $52
Current: $24.80
Upside: +109.68%
Pulmatrix
Aug 15, 2023
Reiterates: Buy
Price Target: $10
Current: $2.04
Upside: +390.20%
BioCryst Pharmaceuticals
Aug 4, 2023
Reiterates: Buy
Price Target: $30
Current: $4.16
Upside: +621.15%
Bellerophon Therapeutics
Jun 6, 2023
Maintains: Buy
Price Target: $30 → $2
Current: $0.06
Upside: +3,529.76%
Corbus Pharmaceuticals Holdings
Mar 8, 2023
Reiterates: Buy
Price Target: $3
Current: $34.25
Upside: -91.24%
MEI Pharma
Feb 13, 2023
Maintains: Buy
Price Target: $100 → $40
Current: $3.05
Upside: +1,211.48%
Matinas BioPharma Holdings
Jan 31, 2023
Reiterates: Buy
Price Target: $3
Current: $0.18
Upside: +1,576.91%
Eloxx Pharmaceuticals
May 9, 2022
Maintains: Neutral
Price Target: $40 → $20
Current: $0.81
Upside: +2,382.04%
Amarin Corporation
May 5, 2022
Downgrades: Neutral
Price Target: $10 → $3
Current: $0.87
Upside: +242.90%
Aldeyra Therapeutics
Apr 27, 2022
Assumes: Buy
Price Target: $15
Current: $3.93
Upside: +281.68%
Aprea Therapeutics
Mar 16, 2022
Maintains: Neutral
Price Target: $80 → $40
Current: $5.20
Upside: +669.23%
Ocuphire Pharma
Nov 24, 2021
Initiates: Buy
Price Target: n/a
Current: $1.61
Upside: -
Telesis Bio
Mar 18, 2021
Maintains: Buy
Price Target: n/a
Current: $0.32
Upside: -